Published in Brain Res on June 29, 1998
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J (2006) 1.37
Cdk5 regulates the organization of Nestin and its association with p35. Mol Cell Biol (2003) 1.24
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.19
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res (2012) 1.08
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease. Mol Biol Cell (2008) 1.07
Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem (2010) 1.05
Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett (2006) 0.97
Physiological regulation of tau phosphorylation during hibernation. J Neurochem (2008) 0.94
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem (2013) 0.94
Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol (2006) 0.93
Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better? Curr Neurovasc Res (2005) 0.93
Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease. Front Mol Neurosci (2009) 0.89
Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci (2007) 0.87
Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity. Mol Cell Neurosci (2011) 0.87
Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function. Cell Death Differ (2011) 0.86
Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease. PLoS One (2014) 0.85
Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease [corrected]. PLoS One (2013) 0.85
Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid Med Cell Longev (2013) 0.84
Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age (Dordr) (2008) 0.84
Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. J Biol Chem (2013) 0.83
IGF-IR in neuroprotection and brain tumors. Front Biosci (Landmark Ed) (2009) 0.83
Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young mice. Anesthesiology (2014) 0.82
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors. Sci Rep (2012) 0.82
Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease? Curr Alzheimer Res (2013) 0.82
Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev (2015) 0.80
Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine. Invest New Drugs (2009) 0.78
The calcium-binding protein EFhd2 modulates synapse formation in vitro and is linked to human dementia. J Neuropathol Exp Neurol (2014) 0.78
No association of CDK5 genetic variants with Alzheimer's disease risk. BMC Med Genet (2009) 0.77
Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology (Berl) (2014) 0.76
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement (2016) 0.76
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers Res Ther (2016) 0.75
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet (2000) 7.31
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Abnormal fibrils from scrapie-infected brain. Acta Neuropathol (1981) 5.35
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett (1986) 3.36
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol (1984) 2.97
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol (1984) 2.70
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med (1998) 2.68
Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci (1997) 2.59
Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s). Acta Neuropathol (1984) 2.58
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol (2000) 2.37
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc (2001) 2.30
Education and dementia: what lies behind the association? Neurology (2007) 2.26
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
Evidence that Alzheimer neurofibrillary tangles originate from neurotubules. Lancet (1979) 2.22
Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ (1996) 2.20
Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology (1997) 2.14
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord (2006) 2.08
Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2010) 2.07
Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem (1993) 2.05
Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology (1991) 2.05
Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem (1992) 2.04
Simultaneous liquid chromatographic determination of seventeen of the major monoamine neurotransmitters, precursors and metabolites. II. Assessment of human brain and cerebrospinal fluid concentrations. J Chromatogr (1987) 2.04
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Scanning electron microscopic study of virulent and avirulent colonies of Neisseria gonorrhoeae. Infect Immun (1975) 2.03
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem (2000) 2.00
Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol (1997) 1.99
Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc (1988) 1.95
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology (2010) 1.88
Ultrastructure of paired helical filaments of Alzheimer's neurofibrillary tangle. J Neuropathol Exp Neurol (1984) 1.86
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem (1995) 1.86
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology (2007) 1.81
Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology (1999) 1.78
Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm (Vienna) (2004) 1.78
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry (1979) 1.71
Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol (1992) 1.71
Distribution of different fiber types in human skeletal muscles: effects of aging studied in whole muscle cross sections. Muscle Nerve (1983) 1.70
The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology (1999) 1.67
Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology (2010) 1.67
Protein changes in senile dementia. Brain Res (1974) 1.65
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63
The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med (2009) 1.57
Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med (1996) 1.57
Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron (1995) 1.56
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Underdiagnosis and poor documentation of acute confusional states in elderly hip fracture patients. J Am Geriatr Soc (1991) 1.55
Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology (1992) 1.54
Heart failure and Alzheimer's disease. J Intern Med (2014) 1.54
Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol (2001) 1.54
Simulated movement termination for balance recovery: can movement strategies be sought to maintain stability in the presence of slipping or forced sliding? J Biomech (1999) 1.52
Role of feedforward control of movement stability in reducing slip-related balance loss and falls among older adults. J Neurophysiol (2003) 1.52
Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry (1997) 1.52
Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int (2006) 1.52